A patient will be eligible for inclusion in the study only if all of the following criteria
        are met:
          1. Parents/legal guardians of the patient have the ability to understand the requirements
             of the study and have demonstrated a willingness to have their child comply with all
             study procedures by signing an institutional review board-approved informed consent
             form. Where applicable, assent of the patient has also been obtained for all study
             procedures prior to any study-related activities.
          2. Patient is between 6 months and <18 years of age at screening.
          3. Patient has chronic kidney disease receiving in-center hemodialysis at least twice
             weekly for at least 3 months prior to screening.
          4. Patient is receiving adequate hemodialysis as assessed by the investigator and based
             on a single pool Kt/V measurement >1.2.
          5. Patient has a vascular access (tunneled catheter, AV fistula or AV graft) suitable to
             support blood flows for hemodialysis treatment.
          6. Patient has a body mass of ≥11 lbs (5 kg).
          7. Patient is iron-replete as measured by a TSAT ≥ 20% and a ferritin >100 µg/L at
             screening.
          8. Patient has a whole blood Hgb concentration of ≥ 9.5 g/dL at screening.
          9. If the patient is female, she must be pre-pubertal, have had documented surgical
             sterilization prior to Baseline admission, or be practicing adequate birth control.
             All female patients who have reached menarche must have a negative serum pregnancy
             test during screening. It is the investigator's responsibility to determine whether
             the patient has adequate birth control for study participation.
         10. Patients who have experienced a previous adverse event with IV iron products are
             eligible to participate in this study if the agent that caused the event is not
             administered during the Baseline period.
        Exclusion Criteria:
        A patient will not be eligible for inclusion in the study if any of the following criteria
        apply:
          1. Patient is positive for human immunodeficiency virus (HIV) or hepatitis B by history.
          2. Patient is receiving intravenous or oral antibiotics or antifungals for any infectious
             process. (Prophylactic antibiotics administered on a regular basis are allowed.
             Patients may enter the study once the infection has cleared.)
          3. Patient has evidence of an ongoing active inflammatory process (e.g., systemic lupus
             erythematosus, acute or chronic active hepatitis, etc.) requiring treatment.
          4. Patient has been dosed in an investigational drug study within the 30 days prior to
             Baseline.
          5. Administration of iron containing phosphate binder ferric citrate (Auryxia) or
             sucroferric oxyhydroxide (Velphoro) within 2 weeks prior to Baseline. (Patient is only
             eligible if iron based binders are stopped at least 2 weeks prior to Baseline).